Compare Huntington Bancshares Incorporated (HBAN) vs Recursion Pharmaceuticals Inc (RXRX) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Huntington Bancshares Incorporated vs Recursion Pharmaceuticals Inc — how do they compare? Huntington Bancshares Incorporated trades at $18.21 (market cap $36.62B), while Recursion Pharmaceuticals Inc trades at $2.93 (market cap $1.53B). The key difference: Huntington Bancshares Incorporated is far larger — about 23.9× Recursion Pharmaceuticals Inc's market cap, and Huntington Bancshares Incorporated pays a 3.43% dividend while Recursion Pharmaceuticals Inc pays none. Which is the better fit depends on your goals.
| HBAN | RXRX | |
|---|---|---|
Market Cap | $36.62B | $1.53B |
Sector | Financials | Health |
52-Week High | $19.27 | $6.79 |
52-Week Low | $15.02 | $2.84 |
Dividend Yield | 3.43% | — |
Enterprise Value | — | $946.50M |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Huntington Bancshares (HBAN) trades at $18.07, down 0.99% on the day, with a bullish technical signal from moving averages but a neutral reading from oscillators. The company reported Q1 2026 EPS of $0.25, beating expectations, with revenue growth to $8.13 billion in 2025. Recent news highlights expansion in Texas and a strong fintech partnership award.
HBAN presents a mixed outlook; analyst consensus is a Buy with a $20.25 price target, implying upside, but risks include integration challenges from acquisitions and competitive pressures in regional banking. Earnings growth and margin stability are key catalysts, though debt levels have risen steadily.
RXRX trades at $2.89, down 1.87% on the day, reflecting a challenging fundamental backdrop with a net income margin of -851.51% and negative cash flow from operations. The technical picture is bearish, though the stock has beaten earnings estimates for the last three quarters. Recent news highlights its AI-driven drug discovery platform and significant institutional interest, including purchases by Cathie Wood's Ark Invest.
The outlook remains speculative; the high analyst price target of $7.83 suggests significant upside potential, but this is contingent on the company successfully commercializing its pipeline. Key risks include persistent cash burn, intense competition, and the inherent uncertainty of clinical-stage biotech development.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
About Huntington Bancshares Incorporated
Huntington Bancshares is a regional bank holding company headquartered in Columbus, Ohio. The bank has a network of branches and ATMs across eight Midwestern states. Founded in 1866, Huntington National Bank and its affiliates provide consumer, small-business, commercial, treasury management, wealth management, brokerage, trust, and insurance services. Huntington also provides auto dealer, equipment finance, national settlement, and capital market services that extend beyond its core states.
Read more on HBAN →About Recursion Pharmaceuticals Inc
Recursion Pharmaceuticals, Inc. is a clinical-stage biotechnology company leveraging artificial intelligence (AI) and machine learning to industrialize drug discovery. The company's unique approach combines one of the world's largest biological and chemical datasets with automated wet-lab and computational systems to map human biology and identify potential therapeutic candidates across a range of diseases, including oncology and rare diseases. Recursion aims to accelerate the traditionally slow and expensive process of drug development.
Read more on RXRX →
